Study analysis · Journal of clinical lipidology · 2019
Can a cheap, old vitamin slash liver fat by nearly half? A new review says maybe.
Niacin (vitamin B3) might help treat fatty liver disease, but the evidence is still weak.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
Imagine a scientist wrote a report saying 'I think niacin might help with fatty liver disease' and then showed experiments in mice and cells, plus one small test in people without comparing them to a control group. This is like a hint, not proof. We cannot say for sure that niacin works in people based on this.
What’s the bottom line?
Researchers looked at studies on niacin (vitamin B3) for fatty liver disease. They found that in animals and cells, niacin helps stop fat buildup and inflammation. In a small study with people, niacin reduced liver fat by almost half. But more studies are needed.
How strong is this study?
This report is like a summary of some studies the author picked, not a careful search of all studies. The only human test was small and didn't compare to a placebo, so we can't trust the results much. It's a good starting point, but we need bigger, fairer tests.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
0 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control groupno control group
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 51 / 100
Probability of being correct
Systematic reviews and meta-analyses of cohort studies. They sit above a single cohort study but below a single randomized trial, because the underlying evidence is still observational.
This design cannot establish causation — the findings describe an association, not a cause. This is a narrative review summarizing animal, in vitro, and uncontrolled human data. No controlled trials; cannot establish causation.
COI Unknown
Could not determine conflict of interest status
No conflict of interest or funding information available from the provided text.
The provided text is only the abstract and highlights; full author affiliations and COI disclosures are not visible.
Key takeaways
- 01
In a small human study, niacin reduced liver fat by 47%.
- 02
In animals, niacin stopped fat accumulation and fibrosis.
- 03
A 47% reduction in liver fat is significant, but the study was not controlled, so it's not definitive.
Surprising findings
- Niacin, used for decades for cholesterol, may be repurposed for fatty liver.Niacin is known for causing flushing and has fallen out of favor for heart disease, but this review suggests a new use.
Practical takeaways
Consult your doctor about niacin if you have NAFLD and high triglycerides, but do not self-treat.
Niacin can cause flushing, liver toxicity at high doses, and interactions with other drugs.
low confidenceWhy this study matters
The 47% liver fat reduction
In an uncontrolled trial of 39 patients with high triglycerides and fatty liver, 6 months of extended-release niacin reduced liver fat by 47%, improved liver enzymes, and lowered CRP.
A nearly 50% drop with an inexpensive, widely available vitamin is remarkable, even if early data.
Niacin works at all three stages of NAFLD
Animal and cell studies show niacin inhibits steatosis, inflammation, and fibrosis, likely via oxidative stress reduction and DGAT2 inhibition.
Most drugs target only one stage; niacin might hit all three, making it a potential multi-target therapy.
Why we need randomized controlled trials
Despite promising animal and uncontrolled human data, the authors stress that a placebo-controlled double-blind RCT is needed to confirm efficacy and safety.
Without a control group, the 47% reduction could be due to other factors. This shows the gap between hype and proof.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Researchers looked at studies on niacin (vitamin B3) for fatty liver disease. They found that in animals and cells, niacin helps stop fat buildup and inflammation. In a small study with people, niacin reduced liver fat by almost half. But more studies are needed.
Research results
In a small human study, niacin reduced liver fat by 47%. In animals, niacin stopped fat accumulation and fibrosis.
What this means - more context
A 47% reduction in liver fat is significant, but the study was not controlled, so it's not definitive.
To review evidence for niacin as a treatment for nonalcoholic fatty liver disease (NAFLD) and its complications.
Niacin inhibits and reverses hepatic steatosis and inflammation in animal models and cell cultures, and prevents fibrosis. An uncontrolled clinical trial in 39 patients showed a 47% reduction in liver fat and improvements in liver enzymes and CRP. Mechanism involves oxidative stress reduction and DGAT2 inhibition. The authors advocate for further controlled trials.
Methods Used
Narrative review of animal studies, in vitro cell culture studies, and one uncontrolled clinical trial.
Main Finding
Niacin may reduce liver fat by 47% and improve inflammation and fibrosis markers, suggesting potential repurposing for NAFLD, but controlled trials are needed.
Confidence Level
Low - based on preclinical and uncontrolled clinical data only.
Study Flags
Red Flags
- •Narrative review, not systematic or meta-analysis
- •Clinical evidence from uncontrolled trial only
- •Authors explicitly call for RCTs, indicating uncertainty
Surprising Findings
Niacin, used for decades for cholesterol, may be repurposed for fatty liver.
Niacin is known for causing flushing and has fallen out of favor for heart disease, but this review suggests a new use.
Practical Takeaways
Consult your doctor about niacin if you have NAFLD and high triglycerides, but do not self-treat.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 51 / 100
Probability of being correct
Systematic reviews and meta-analyses of cohort studies. They sit above a single cohort study but below a single randomized trial, because the underlying evidence is still observational.
Narrative Review
Subject
Lower probability
on the GRADE evidence scale
Imagine a scientist wrote a report saying 'I think niacin might help with fatty liver disease' and then showed experiments in mice and cells, plus one small test in people without comparing them to a control group. This is like a hint, not proof. We cannot say for sure that niacin works in people based on this.
Strengths
- Includes a review of mechanisms from animal/in vitro studies
- Highlights the need for RCTs
Weaknesses
- Narrative review without systematic search or evidence quality assessment
- Relies on animal and in vitro data
- Only one uncontrolled human trial with no control group
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Researchers looked at studies on niacin (vitamin B3) for fatty liver disease. They found that in animals and cells, niacin helps stop fat buildup and inflammation. In a small study with people, niacin reduced liver fat by almost half. But more studies are needed.
Research results
In a small human study, niacin reduced liver fat by 47%. In animals, niacin stopped fat accumulation and fibrosis.
What this means - more context
A 47% reduction in liver fat is significant, but the study was not controlled, so it's not definitive.
To review evidence for niacin as a treatment for nonalcoholic fatty liver disease (NAFLD) and its complications.
Niacin inhibits and reverses hepatic steatosis and inflammation in animal models and cell cultures, and prevents fibrosis. An uncontrolled clinical trial in 39 patients showed a 47% reduction in liver fat and improvements in liver enzymes and CRP. Mechanism involves oxidative stress reduction and DGAT2 inhibition. The authors advocate for further controlled trials.
Methods Used
Narrative review of animal studies, in vitro cell culture studies, and one uncontrolled clinical trial.
Main Finding
Niacin may reduce liver fat by 47% and improve inflammation and fibrosis markers, suggesting potential repurposing for NAFLD, but controlled trials are needed.
Confidence Level
Low - based on preclinical and uncontrolled clinical data only.
Study Flags
Red Flags
- •Narrative review, not systematic or meta-analysis
- •Clinical evidence from uncontrolled trial only
- •Authors explicitly call for RCTs, indicating uncertainty
Surprising Findings
Niacin, used for decades for cholesterol, may be repurposed for fatty liver.
Niacin is known for causing flushing and has fallen out of favor for heart disease, but this review suggests a new use.
Practical Takeaways
Consult your doctor about niacin if you have NAFLD and high triglycerides, but do not self-treat.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 51 / 100
Probability of being correct
Systematic reviews and meta-analyses of cohort studies. They sit above a single cohort study but below a single randomized trial, because the underlying evidence is still observational.
Narrative Review
Subject
Lower probability
on the GRADE evidence scale
Imagine a scientist wrote a report saying 'I think niacin might help with fatty liver disease' and then showed experiments in mice and cells, plus one small test in people without comparing them to a control group. This is like a hint, not proof. We cannot say for sure that niacin works in people based on this.
Strengths
- Includes a review of mechanisms from animal/in vitro studies
- Highlights the need for RCTs
Weaknesses
- Narrative review without systematic search or evidence quality assessment
- Relies on animal and in vitro data
- Only one uncontrolled human trial with no control group
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This report is like a summary of some studies the author picked, not a careful search of all studies. The only human test was small and didn't compare to a placebo, so we can't trust the results much. It's a good starting point, but we need bigger, fairer tests.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
0 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control groupno control group
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 51 / 100
Probability of being correct
Systematic reviews and meta-analyses of cohort studies. They sit above a single cohort study but below a single randomized trial, because the underlying evidence is still observational.
This design cannot establish causation — the findings describe an association, not a cause. This is a narrative review summarizing animal, in vitro, and uncontrolled human data. No controlled trials; cannot establish causation.
COI Unknown
Could not determine conflict of interest status
No conflict of interest or funding information available from the provided text.
The provided text is only the abstract and highlights; full author affiliations and COI disclosures are not visible.